Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial

Antzeko izenburuak

• Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial
  nork: Sutherland, Katherine A., et al.
  Argitaratua: (2016)
• Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa
  nork: Sutherland, Katherine A., et al.
  Argitaratua: (2015)
• Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa
  nork: Pillay, D, et al.
  Argitaratua: (2010)
• Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1
  nork: McCormick, Adele L., et al.
  Argitaratua: (2011)
• Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa
  nork: Goodall, Ruth L., et al.
  Argitaratua: (2017)